You have been successfully logged out.
Patient selection and CAR T-cell therapy 5 years on
CAR T-cell therapy was launched in the UK over 5 years ago. Advancing treatment of some blood cancers, it is a novel and potentially curative therapeutic option that uses a patient’s own white blood cells to create a one-time treatment.1
The panel of experts will be discussing the clinical and non-clinical factors to take into consideration for referring patients for CAR T-cell therapy (specifically in DLBCL).
(Webinar recorded March 2024. Full video: 32 minutes)
DR WENDY OSBORNE
Consultant Haematologist, Freeman Hospital
DR ROBIN SANDERSON
Consultant Haematologist-Oncologist, King’s College Hospital
DR KAWAI YIP [SKYE]
(Referring Centre) Consultant Haematologist, Darent Valley Hospital
April 2025 UKI-YES-0115
Adverse events should be reported
Reporting forms and information can be found at www.mhra.gov.uk/yellowcard or via the Yellow Card app (download from the Apple App Store or Google Play Store). Adverse events should also be reported to Gilead to [email protected] or +44 (0) 1223 897500.